Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Asia-Pacific Diabetes Care Drugs Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 90 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 90 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.
Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.
The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.
Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia.
Scope of the Report
The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.
Key Market Trends
Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.
The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.
SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors.
Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.
China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.
In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.
Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.
China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market.
The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.
Competitive Landscape
The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Oral Anti-diabetic Drugs
5.1.1.1 Biguanides (Value and Volume 2012-2024)
5.1.1.1.1 Metformin
5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
5.1.1.2.1 Alpha – Glucosidase Inhibitors
5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
5.1.1.3.1 Bromocriptin (Cycloset)
5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.4.1 Invokana (Canagliflozin)
5.1.1.4.2 Jardiance (Empagliflozin)
5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4.4 Suglat (Ipragliflozin)
5.1.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
5.1.1.5.1 Januvia (Sitagliptin)
5.1.1.5.2 Onglyza (Saxagliptin)
5.1.1.5.3 Tradjenta (Linagliptin)
5.1.1.5.4 Vipidia/Nesina (Alogliptin)
5.1.1.5.5 Galvus (Vildagliptin)
5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)
5.1.1.6.1 Sulfonylureas
5.1.1.7 Meglitinides (Value and Volume 2012-2024)
5.1.1.7.1 Meglitinides
5.1.2 Insulin
5.1.2.1 Basal or Long-acting Insulins
5.1.2.1.1 Lantus (Insulin Glargine)
5.1.2.1.2 Levemir (Insulin Detemir)
5.1.2.1.3 Toujeo (Insulin Glargine)
5.1.2.1.4 Tresiba (Insulin Degludec)
5.1.2.1.5 Basaglar (Insulin Glargine)
5.1.2.2 Bolus or Fast-acting Insulins
5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)
5.1.2.2.2 Humalog (Insulin Lispro)
5.1.2.2.3 Apidra (Insulin Glulisine)
5.1.2.3 Traditional Human Insulins
5.1.2.3.1 Novolin/Actrapid/Insulatard
5.1.2.3.2 Humilin
5.1.2.3.3 Insuman
5.1.2.4 Biosimilar Insulins
5.1.2.4.1 Insulin Glargine Biosimilars
5.1.2.4.2 Human Insulin Biosimilars
5.1.3 Non-insulin Injectable Drugs
5.1.3.1 GLP-1 Receptor Agonists
5.1.3.1.1 Victoza (Liraglutide)
5.1.3.1.2 Byetta (Exenatide)
5.1.3.1.3 Bydureon (Exenatide)
5.1.3.1.4 Trulicity (Dulaglutide)
5.1.3.1.5 Lyxumia (Lixisenatide)
5.1.3.2 Amylin Analogue
5.1.3.2.1 Symlin (Pramlintide)
5.1.4 Combination Drugs
5.1.4.1 Insulin Combinations
5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)
5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
5.1.4.2 Oral Combination
5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)
5.2 Geography
5.2.1 Asia-Pacific
5.2.1.1 Australia (Value and Volume 2012-2024)
5.2.1.1.1 Oral Anti-diabetic Drugs
5.2.1.1.2 Insulin
5.2.1.1.3 Non-Insulin Injectable Drugs
5.2.1.1.4 Combination Drugs
5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.2 China (Value and Volume 2012-2024)
5.2.1.2.1 Oral Anti-diabetic Drugs
5.2.1.2.2 Insulin
5.2.1.2.3 Non-Insulin Injectable Drugs
5.2.1.2.4 Combination Drugs
5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.3 India (Value and Volume 2012-2024)
5.2.1.3.1 Oral Anti-diabetic Drugs
5.2.1.3.2 Insulin
5.2.1.3.3 Non-Insulin Injectable Drugs
5.2.1.3.4 Combination Drugs
5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.4 Indonesia (Value and Volume 2012-2024)
5.2.1.4.1 Oral Anti-diabetic Drugs
5.2.1.4.2 Insulin
5.2.1.4.3 Non-Insulin Injectable Drugs
5.2.1.4.4 Combination Drugs
5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.5 Japan (Value and Volume 2012-2024)
5.2.1.5.1 Oral Anti-diabetic Drugs
5.2.1.5.2 Insulin
5.2.1.5.3 Non-Insulin Injectable Drugs
5.2.1.5.4 Combination Drugs
5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.6 Malaysia (Value and Volume 2012-2024)
5.2.1.6.1 Oral Anti-diabetic Drugs
5.2.1.6.2 Insulin
5.2.1.6.3 Non-Insulin Injectable Drugs
5.2.1.6.4 Combination Drugs
5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.7 Philippines (Value and Volume 2012-2024)
5.2.1.7.1 Oral Anti-diabetic Drugs
5.2.1.7.2 Insulin
5.2.1.7.3 Non-Insulin Injectable Drugs
5.2.1.7.4 Combination Drugs
5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.8 South Korea (Value and Volume 2012-2024)
5.2.1.8.1 Oral Anti-diabetic Drugs
5.2.1.8.2 Insulin
5.2.1.8.3 Non-Insulin Injectable Drugs
5.2.1.8.4 Combination Drugs
5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.9 Thailand (Value and Volume 2012-2024)
5.2.1.9.1 Oral Anti-diabetic Drugs
5.2.1.9.2 Insulin
5.2.1.9.3 Non-Insulin Injectable Drugs
5.2.1.9.4 Combination Drugs
5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.10 Vietnam (Value and Volume 2012-2024)
5.2.1.10.1 Oral Anti-diabetic Drugs
5.2.1.10.2 Insulin
5.2.1.10.3 Non-Insulin Injectable Drugs
5.2.1.10.4 Combination Drugs
5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)
5.2.1.11.1 Oral Anti-diabetic Drugs
5.2.1.11.2 Insulin
5.2.1.11.3 Non-Insulin Injectable Drugs
5.2.1.11.4 Combination Drugs
5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Takeda
7.1.2 Pfizer
7.1.3 Eli Lilly
7.1.4 Janssen Pharmaceuticals
7.1.5 Astellas
7.1.6 Boehringer Ingelheim
7.1.7 Merck And Co.
7.1.8 AstraZeneca
7.1.9 Bristol Myers Squibb
7.1.10 Novartis
7.1.11 Sanofi
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Oral Anti-diabetic Drugs
Biguanides (Value and Volume 2012-2024)
Metformin
Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)
Alpha – Glucosidase Inhibitors
Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)
Bromocriptin (Cycloset)
Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)
Januvia (Sitagliptin)
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina (Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas (Value and Volume 2012-2024)
Sulfonylureas
Meglitinides (Value and Volume 2012-2024)
Meglitinides
Insulin
Basal or Long-acting Insulins
Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast-acting Insulins
NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins
Novolin/Actrapid/Insulatard
Humilin
Insuman
Biosimilar Insulins
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Non-insulin Injectable Drugs
GLP-1 Receptor Agonists
Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue
Symlin (Pramlintide)
Combination Drugs
Insulin Combinations
NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combination
Janumet (Sitagliptin and Metformin HCl)
Geography
Asia-Pacific
Australia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
China (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
India (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Indonesia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Japan (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Malaysia (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Philippines (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
South Korea (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Thailand (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Vietnam (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Rest of Asia Pacific (Value and Volume 2012-2024)
Oral Anti-diabetic Drugs
Insulin
Non-Insulin Injectable Drugs
Combination Drugs
By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.
Scope of the Report
The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.
Key Market Trends –
Jardiance is Leading the SGLT2 Market.
Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).
65% of the Market Share is Occupied by North America.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.
Competitive Landscape
The SGLT2 market is highly consolidated, with a few significant manufacturers having a global market presence.
The joint ventures that occurred between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT2 class drug.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.1 Invokana (Canagliflozin)
5.1.1.2 Jardiance (Empagliflozin)
5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4 Suglat (Ipragliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2 Europe
5.2.2.1 France (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.2 Germany (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.4 Spain (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.2 Brazil (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.2 South Korea (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.3 China (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.4 India (Value and Volume 2012-2024)
5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.5 Australia (Value and Volume 2012-2024)
5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.6 Vietnam (Value and Volume 2012-2024)
5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.7 Malaysia (Value and Volume 2012-2024)
5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.8 Indonesia (Value and Volume 2012-2024)
5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.9 Philippines (Value and Volume 2012-2024)
5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.10 Thailand (Value and Volume 2012-2024)
5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Astellas
7.1.4 Boehringer Ingelheim
7.1.5 AstraZeneca
7.1.6 Bristol Myers Squibb
7.2 MARKET SHARE ANALYSIS
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Astellas
7.2.4 Boehringer Ingelheim
7.2.5 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Canada (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of North America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Europe
France (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Germany (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Italy (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Spain (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
UK (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Russia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Latin America
Mexico (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Brazil (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Iran (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Egypt (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Oman (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Middle & Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Proton Pump Inhibitors Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 12-06-2019
Market Overview
The major factors for the growth of the proton pump inhibitors market include the increasing prevalence of gastroesophageal reflux disease (GERD) and the rising acceptance of novel drug delivery systems.
Gastroesophageal reflux disease is a chronic condition, where the stomach content comes back up into the esophagus resulting in either symptoms or complications. The most frequently reported symptoms of GERD are heartburn, a burning discomfort that begins behind the breastbone and radiates to the neck and throat, and acid regurgitation, which is characterized as a bitter, sour-tasting fluid.
In addition to the increase in prevalence, people with risk factors, such as obesity, tobacco use, and others, are also increasing in almost every part of the world. Obesity, which is the major risk factor of GERD, is increasing rapidly in developed countries, such as the United States, the United Kingdom, and others. The increasing prevalence of GERD, along with the growing risk factor population, is likely to lead to the growth in the demand for proton pump inhibitors, which in turn, will drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
Scope of the Report
As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs, whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The market studied is further segmented on the basis of drug type and geography. The drug type segmentation includes OTC and prescription drugs.
Key Market Trends
Esomeprazole is Expected to Account for the Largest Market Share in Drug Type
Nexium is one among the leading revenue generating drugs globally, and it is used to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug till before 28th March 2014, the date when FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future. There are several benefits associated with OTC drugs, such as low price, enhanced accessibility, and no regular monitoring. As OTC drugs are sold without any prescription, the consumer need not go to any doctor for a prescription, which reduces the overall cost, and hence these drugs have the potential to increase their adoption rate. Accessibility is another vital factor for the consumption of any medicine, and better accessibility may definitely result in more revenue. However, OTC drugs have some disadvantages as well. As they can be purchased without any prescription, anyone can buy as many as they want and leave the scope for their overuse.
Additionally, there are several minor side effects, such as nausea, headaches, dry mouth, diarrhea, allergic reaction, and others, as well as some major side effects, such as kidney disease, dementia, and others associated with its use, which can affect the adoption rate, and hence can be the restraining factors for the growth of the market.
North America Accounted for the Largest Share in the Global Market
North America holds a major share in the proton pump inhibitors market and is expected to show a similar trend over the forecast period, without significant fluctuations. There is a rising prevalence of GERD in the United States, Canada, and Mexico. Furthermore, GERD affects up to 20% of adults in the United States, therefore making the disease an important concern. Proton pump inhibitors are the widely prescribed drugs, and increased PPI use has been observed in the US ambulatory settings. Furthermore, many firms are expected to spend heavily on promoting their brands. The widespread use of these has recently gained attention from the American Board of Internal Medicine’s campaign to promote the appropriate use of PPIs.
Competitive Landscape
The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring the market share by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 OTC (Over-the-Counter) Drugs
5.1.1.1 Omeprazole
5.1.1.2 Lansoprazole
5.1.1.3 Esomeprazole
5.1.1.4 Other OTC Drugs
5.1.2 Prescription Drugs
5.1.2.1 Rabeprazole
5.1.2.2 Dexlansoprazole
5.1.2.3 Pantoprazole
5.1.2.4 Other Prescription Drugs
5.2 Geography
5.2.1 North America
5.2.1.1 US
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 UK
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug Type
OTC (Over-the-Counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Asia-Pacific Self monitoring Blood Glucose Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 80 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 80 pages
- Published: 12-06-2019
Market Overview
The Asia-Pacific self-monitoring blood glucose devices market is segmented into blood glucose meters, blood glucose testing strips, and lancets. Self-monitoring blood glucose (SMBG) devices markets across the Asia Pacific are still in their growing phases. In China, the market size for self-monitoring blood glucose devices is projected to reach USD 0.9 billion by 2019. The market is driven by the increasing diabetic population and continuous innovations in the diagnosis and treatment of diabetes. The Chinese and Japanese markets are the most competitive ones, with a significant number of market players and strong local competition.
Asia-Pacific is at the fore front of the diabetic epidemic, with more than 200 million people suffering from diabetes in 2013, and this number is expected to increase in the coming years. 6.3% of the total APAC population was suffering from diabetes in 2015. With the increasing rate of diabetes cases, self-monitoring with glucose meters and strips has become an important aspect of diabetes care and management.
Scope of the Report
This report includes a detailed study about self-monitoring blood glucose devices, test strips and lancets in the Asia-Pacific market, and further study includes hospital usage and home usage of glucometer devices, test strips, and lancets, in each country.
Key Market Trends
In Asia-Pacific, Glucometer Device Segment Registered the Highest CAGR with 10.6%
The personal-use glucometer is expected to see high sales in the future, owing to the rising awareness and reducing costs associated with the glucometer.
Glucometers, which can be used for critically ill patients, have been approved, like the finger stick glucometer that is available in the market.
The glucometer segment is expected to continue to expand in the future, due to the innovative developments in the same, such as glucometers that can be plugged into smartphones using headphone jack, to automatically record the values. Additionally, making the devices light with long efficient batteries would further promote the adoption of glucometer.
China has the Highest Market Share in Asia-Pacific and Will Continue to Grow in the Future with the CAGR of 7.63%
China faces the largest diabetes epidemic in the world. The number of insulin users increased among the Chinese population, with an increase in Type 1 and Type 2 patients. The trend of self-monitoring blood glucose levels increased more among the Type 1 population. The Chinese blood glucose monitoring market has majorly increased to monitor glycosylated haemoglobin (HbA1c) levels.
In 2015, in the Chinese blood glucose monitoring devices market, the consumables accounted for 88.6%, of which, 75.88% of the market share was held by test strips and the 11.2% was occupied by glucometer devices.
Competitive Landscape
The Asia-Pacific self-monitoring blood glucose devices market is highly fragmented with few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers.
Mergers and acquisitions that happened between players in the recent past helped the companies to strengthen their market presence; for instance, Ascensia Diabetes Care was established itself in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings (formerly known as Panasonic Healthcare Holdings).
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Self -monitoring Blood Glucose Devices
5.1.1 By Component (Market Size, Value and Volume)
5.1.1.1 Glucometer Devices
5.1.1.2 Test Strips
5.1.1.3 Lancets
5.1.2 By End User
5.1.2.1 Hospital (Market Size, Value and Volume)
5.1.2.1.1 Glucometer Devices
5.1.2.1.2 Test Strips
5.1.2.1.3 Lancets
5.1.2.2 Personal (Market Size, Value and Volume)
5.1.2.2.1 Glucometer Devices
5.1.2.2.2 Test Strips
5.1.2.2.3 Lancets
5.2 By Geography
5.2.1 Asia-Pacific
5.2.1.1 Japan (Market Size, Value and Volume)
5.2.1.1.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.1.2 By End User (Hospital and Home)
5.2.1.1.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.2 South Korea (Market Size, Value and Volume)
5.2.1.2.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.2.2 By End User (Hospital and Home)
5.2.1.2.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.3 China (Market Size, Value and Volume)
5.2.1.3.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.3.2 By End User (Hospital and Home)
5.2.1.3.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.4 India (Market Size, Value and Volume)
5.2.1.4.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.4.2 By End User (Hospital and Home)
5.2.1.4.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.5 Australia (Market Size, Value and Volume)
5.2.1.5.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.5.2 By End User (Hospital and Home)
5.2.1.5.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.6 Vietnam (Market Size, Value and Volume)
5.2.1.6.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.6.2 By End User (Hospital and Home)
5.2.1.6.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.7 Malaysia (Market Size, Value and Volume)
5.2.1.7.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.7.2 By End User (Hospital and Home)
5.2.1.7.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.8 Indonesia (Market Size, Value and Volume)
5.2.1.8.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.8.2 By End User (Hospital and Home)
5.2.1.8.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.9 Philippines (Market Size, Value and Volume)
5.2.1.9.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.9.2 By End User (Hospital and Home)
5.2.1.9.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.10 Thailand (Market Size, Value and Volume)
5.2.1.10.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.10.2 By End User (Hospital and Home)
5.2.1.10.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
5.2.1.11 Rest of Asia-Pacific (Market Size, Value and Volume)
5.2.1.11.1 By Component (Glucometer Device, Test Strips, Lancets)
5.2.1.11.2 By End User (Hospital and Home)
5.2.1.11.3 By Company (Roche, Abbott, Johnson & Johnson, and Others)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Roche
7.1.3 Johnson & Johnson
7.1.4 Arkray
7.1.5 Ascensia Diabetes Care
7.1.6 Agamatrix Inc.
7.1.7 Bionime Corporation
7.1.8 Acon
7.1.9 Medisana
7.1.10 Trivida
7.1.11 I-Sens
7.1.12 Morpen Laboratories
7.1.13 Rossmax
7.2 COMPANY SHARE ANALYSIS
7.2.1 Roche
7.2.2 Johnson & Johnson
7.2.3 Abbott Diabetes Care
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Self-monitoring Blood Glucose Devices
By Component (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By End User
Hospital (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
Personal (Market Size, Value and Volume)
Glucometer Devices
Test Strips
Lancets
By Geography
Asia-Pacific
Japan (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
South Korea (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
China (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
India (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Australia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Vietnam (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Malaysia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Indonesia (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Philippines (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Thailand (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Rest of Asia-Pacific (Market Size, Value and Volume)
By Component (Glucometer Device, Test Strips, Lancets)
By End User (Hospital and Home)
By Company (Roche, Abbott, Johnson & Johnson, and Others)
Patient Portal Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 112 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 112 pages
- Published: 12-06-2019
Market Overview
The increasing growth of the patient portal market has been observed due to the adoption of the patient-centric approach by healthcare payers and increasing demand for electronic health records (EHR) in the market. The current market is also growing as the government is undertaking various initiatives for the patient portals that generally focus on laying down the standards, regulations, and infrastructure for maintaining health records, which may lead to an increase in the demand for patient portal.
The increasing aging population and rise in chronic diseases are putting relentless pressure on the capacity and financial viability of healthcare systems. Healthcare technology, genomics, connected devices, big data analytics, and artificial intelligence are generating vast amounts of health data and insights, which are enabling healthcare providers to make better and faster diagnoses and more informed treatment decisions. These help in transforming the healthcare marketplace from a provider-driven ecosystem to a patient-centric ecosystem. Therefore increasing adoption of the patient-centric approach by healthcare payers and providers is driving the growth of the patient portal market.
The growth of the patient portal market is also due to the increasing geriatric population and the increasing incidence of osteoarthritis disease. The increasing prevalence of osteoarthritis and the introduction of innovative technologies for the treatment of osteoarthritis are found to be the primary factors that are expected to be responsible for the growth of the patient portal market during the forecast period.
The market is also experiencing growth as a result of the increase in demand for EHR (electronic health records), as they have become increasingly more important for patients and providers. EHR systems are becoming increasingly popular as the healthcare industry is moving toward digitization. There are several government initiatives that generally focus on laying down the standards, regulations, and infrastructure for maintaining health records, which may lead to an increase in the demand for patient portals.
Scope of the Report
As per the scope of the report, the patient portal is a web-based access point that is connected with the electronic health records (EHR) systems and is focused on the patient’s access to health records. The patients can share their health information and communicate remotely. These allow patients to look into various data points. Some portals allow patients to check medical history data and view demographics.
Key Market Trends
Integrated Patient Portal Holds the Largest Share in the Portal Segment
The integrated patient portal is more preferred because of the electronic health record (EHR) and holds a significant share in the patient portal market. This portal is likely to dominate the market as it provides more feature for patients, ease of use and allows the patient to access the complete record/history at one place from anywhere and anytime. Currently, the integrated patient portal is commonly used service in the US and expected same way across the globe, and the market to grow positively.
North America was Observed to be the Largest Patient Portal Market
North America has been the largest patient portal market due to wide technological advancements in the region. Countries, such as the United States and Canada, have been successful in implementing IT technologies in their healthcare systems, which as a result, may boost the market growth. Moreover, the presence of developed IT and healthcare infrastructure, promising government initiatives to give patients access to their healthcare data at any time anywhere via the patient portal and in the current healthcare infrastructure, and constantly improving reimbursement scenario are expected to further propel the market growth.
Competitive Landscape
Over the past decade, an opportunity has been presented for pharmaceutical companies to dominate the digital patient engagement arena. The pharmaceutical and medical device companies are also moving toward data-driven models and leveraging IT for business model transformation.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Adoption of Patient-centric Approach by Healthcare Payers
4.2.2 Increase in the Demand for Electronic Health Records (EHRs)
4.2.3 Rising Popularity of Patient Portals Among Geriatric Population
4.2.4 Favorable Government Funding Policies and Initiatives for Implementing Healthcare IT Solutions
4.3 Market Restraints
4.3.1 Data Privacy and Security Concerns
4.3.2 High Cost of Implementation and Deployment
4.3.3 Requirement of Infrastructural Investments to Support Patient Portals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Portal
5.1.1 Integrated Patient Portal
5.1.2 Standalone Patient Portal
5.2 By Delivery Mode
5.2.1 Web-based Delivery
5.2.2 Cloud-based Delivery
5.3 By End User
5.3.1 Provider
5.3.2 Payer
5.3.3 Pharmacy
5.3.4 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 US
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 UK
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allscripts Healthcare Solutions Inc.
6.1.2 Mckesson Corporation
6.1.3 Curemd Healthcare
6.1.4 Athenahealth Inc.
6.1.5 Cerner Corporation
6.1.6 Nextgen Healthcare Information Systems LLC
6.1.7 GE Healthcare
6.1.8 Greenway Health LLC
6.1.9 Medfusion Inc.
6.1.10 Eclinicalworks LLC
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Portal
Integrated Patient Portal
Standalone Patient Portal
By Delivery Mode
Web-based Delivery
Cloud-based Delivery
By End User
Provider
Payer
Pharmacy
Other End Users
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Continuous Glucose Monitoring (CGM) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 75 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 75 pages
- Published: 12-06-2019
Market Overview
As per WHO data, approximately half of all mortality can be associated with high blood glucose levels, which occur before the age of 70 years.
WHO also expects diabetes to be the seventh-leading cause of mortality by 2030. For patients reliant on insulin pumps or daily insulin injections, the CGM establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia.
As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) have been shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose.
The trend follows in children, as well as those who use a CGM on a regular basis. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia.
The current CGM models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid.
Scope of the Report
By the component, the market has been segmented into sensors and receivers.
CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.
Most of the real-time CGMs can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose.
Key Market Trends
Complete Information about Blood Glucose Patterns and Trends
CGMs are used to provide a further descriptive representation of blood glucose patterns and tendencies than what can be achieved by conventional routine checking of glucose levels at set intervals.
The current CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.
Most of the real-time CGMs have the capability to offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, in order to facilitate timely management of blood glucose.
This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, is likely to drive the steady growth of the CGM market during the forecast period.
North America will Maintain Dominance in the Market
In North America, the United States accounted for close to 97% of the market value in 2017. By 2019, the continuous glucose monitoring market in the United States is expected to be valued at USD 1175.5 million.
The United States also accounts for the highest CAGR of 13.2%. It is imperative that the CGM devices be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow.
Competitive Landscape
A major share of the market is held by CGM manufacturers that are concomitant with strategy-based M&A operations and are constantly entering new markets to generate new revenue streams and to boost existing ones.
These measures taken by the market players will ensure a competitive market place, therefore, forcing the companies to experiment with more new technologies, in order to ensure uniqueness in their products.
Also, one of the implications of the competition in the market is that it will ensure a constant decrease in the average selling price of the CGM units produced.
For instance, in December 2017, Abbott’s new FreeStyle Libre Flash Glucose Monitoring System was approved, which is the first continuous blood sugar monitor for diabetics that does not need backup finger prick tests, Abbott has also priced the new device substantially lower than its competitors, which will help the company to strengthen its position in the CGM market during the forecast period.
In January 2016, Ypsomed AG appointed TD Pharmaceutical (Tonghua Dongbau Pharmaceutical) as the exclusive distributor for its range of products in China; hence, reinforcing their pre-existing partnership.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 Market Segmentation
5.1 Continuous Blood Glucose Monitoring
5.1.1 By Component (Value and Volume, 2012 – 2024)
5.1.1.1 Sensors
5.1.1.2 Receivers
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume, 2012 – 2024)
5.2.1.2 Canada (Value and Volume, 2012 – 2024)
5.2.1.3 Rest of North America (Value and Volume, 2012 – 2024)
5.2.2 Europe
5.2.2.1 France (Value and Volume, 2012 – 2024)
5.2.2.2 Germany (Value and Volume, 2012 – 2024)
5.2.2.3 Italy (Value and Volume, 2012 – 2024)
5.2.2.4 Spain (Value and Volume, 2012 – 2024)
5.2.2.5 United Kingdom (Value and Volume, 2012 – 2024)
5.2.2.6 Russia (Value and Volume, 2012 – 2024)
5.2.2.7 Rest of Europe (Value and Volume, 2012 – 2024)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume, 2012 – 2024)
5.2.3.2 Brazil (Value and Volume, 2012 – 2024)
5.2.3.3 Rest of Latin America (Value and Volume, 2012 – 2024)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume, 2012 – 2024)
5.2.4.2 South Korea (Value and Volume, 2012 – 2024)
5.2.4.3 China (Value and Volume, 2012 – 2024)
5.2.4.4 India (Value and Volume, 2012 – 2024)
5.2.4.5 Australia (Value and Volume, 2012 – 2024)
5.2.4.6 Vietnam (Value and Volume, 2012 – 2024)
5.2.4.7 Malaysia (Value and Volume, 2012 – 2024)
5.2.4.8 Indonesia (Value and Volume, 2012 – 2024)
5.2.4.9 Philippines (Value and Volume, 2012 – 2024)
5.2.4.10 Thailand (Value and Volume, 2012 – 2024)
5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume, 2012 – 2024)
5.2.5.2 Iran (Value and Volume, 2012 – 2024)
5.2.5.3 Egypt (Value and Volume, 2012 – 2024)
5.2.5.4 Oman (Value and Volume, 2012 – 2024)
5.2.5.5 South Africa (Value and Volume, 2012 – 2024)
5.2.5.6 Rest of Middle & Africa (Value and Volume, 2012 – 2024)
6 MARKET INDICATORS
6.1 Type 1 Diabetes Population (2012-2024)
6.2 Type 2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Abbott Diabetes Care
7.1.2 Dexcom
7.1.3 Medtronic
7.2 COMPANY SHARE ANALYSIS
7.2.1 Abbott Diabetes Care
7.2.2 Dexcom
7.2.3 Medtronic
7.2.4 Others
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Continuous Blood Glucose Monitoring
By Component (Value and Volume, 2012 – 2024)
Sensors
Receivers
Geography
North America
United States (Value and Volume, 2012 – 2024)
Canada (Value and Volume, 2012 – 2024)
Rest of North America (Value and Volume, 2012 – 2024)
Europe
France (Value and Volume, 2012 – 2024)
Germany (Value and Volume, 2012 – 2024)
Italy (Value and Volume, 2012 – 2024)
Spain (Value and Volume, 2012 – 2024)
United Kingdom (Value and Volume, 2012 – 2024)
Russia (Value and Volume, 2012 – 2024)
Rest of Europe (Value and Volume, 2012 – 2024)
Latin America
Mexico (Value and Volume, 2012 – 2024)
Brazil (Value and Volume, 2012 – 2024)
Rest of Latin America (Value and Volume, 2012 – 2024)
Asia-Pacific
Japan (Value and Volume, 2012 – 2024)
South Korea (Value and Volume, 2012 – 2024)
China (Value and Volume, 2012 – 2024)
India (Value and Volume, 2012 – 2024)
Australia (Value and Volume, 2012 – 2024)
Vietnam (Value and Volume, 2012 – 2024)
Malaysia (Value and Volume, 2012 – 2024)
Indonesia (Value and Volume, 2012 – 2024)
Philippines (Value and Volume, 2012 – 2024)
Thailand (Value and Volume, 2012 – 2024)
Rest of Asia-Pacific (Value and Volume, 2012 – 2024)
Middle East & Africa
Saudi Arabia (Value and Volume, 2012 – 2024)
Iran (Value and Volume, 2012 – 2024)
Egypt (Value and Volume, 2012 – 2024)
Oman (Value and Volume, 2012 – 2024)
South Africa (Value and Volume, 2012 – 2024)
Rest of Middle & Africa (Value and Volume, 2012 – 2024)